Evidence map›Paper›PMID 42830627›Full record

ArticleLung cancer management2026

At-home subcutaneous atezolizumab for non-small cell lung cancer: a prospective, single-arm phase II feasibility study.

Lily Yang, Sana Iman Mutalib, Elizabeth Qi, Andrew Zeng, Jacob Thomas, Robert Hsu, Peter Kuhn, Luciano Nocera, Jorge Nieva

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Lung cancer management, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05340309 (A Phase II Study of Subcutaneous Atezolizumab in NSCLC Patients Using a Decentralized Clinical Trial Model), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05340309 phase2active not recruitingnot on this map

A Phase II Study of Subcutaneous Atezolizumab in NSCLC Patients Using a Decentralized Clinical Trial Model

TypeinterventionalSponsorUniversity of Southern CaliforniaRan2022 to 2027Enrolled5ConditionsLung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8ArmsAtezolizumab and Recombinant Human Hyaluronidase, Survey Administration
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Lily YangKeck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Sana Iman MutalibKeck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Elizabeth QiKeck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Andrew ZengDepartment of Oncology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Jacob ThomasDepartment of Oncology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Robert HsuDepartment of Oncology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Peter KuhnKeck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Luciano NoceraKeck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Jorge NievaDepartment of Oncology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.

Funding

USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Fumito Ito · 1985 to 2026
$181.4M
TOPIC 425 - AUTOMATED MOTION EXTRACTION AND ANALYSIS TO QUANTIFY PATIENT PERFORMANCE STATUS75N91021C00051 · NCI · CANSERA, INC. · PI NOCERA, LUCIANO · 2021 to 2022
$2.3M
NCI NIH HHS 75N91021C00051NCI NIH HHS P30 CA014089
6 · The paper itself

Abstract

purposeFrequent in-clinic cancer treatment can be burdensome, particularly for older adults and patients with limited mobility. This study aimed to assess the safety, feasibility, and patient experience of at-home subcutaneous (SC) atezolizumab injection administration in patients with non-small cell lung cancer (NSCLC). PATIENTS AND

methodsThis feasibility study included five patients with NSCLC treated with atezolizumab SC injections (1,875 mg every 21 days). The first three treatment cycles were administered in clinic, followed by nurse-administered home treatment. Patients underwent routine laboratory testing, telehealth visits, and standard disease monitoring. Safety, injection timeliness, treatment compliance, and patient satisfaction were evaluated over a total of 70 treatment cycles.

resultsOf 70 total SC injections, 65 (93%) were delivered on time. No delays were attributable to atezolizumab SC administration. Two of five patients (40%) experienced an adverse event. Home administration required a shorter measured administration duration than in-clinic treatment (42.3 vs. 86.7 minutes). Digital monitoring engagement was limited. Mean Likert scores showed high overall satisfaction with drug administration (3.3/4) and preference for subcutaneous over intravenous administration (3.2/4).

conclusionAt-home atezolizumab SC administration was feasible in this small feasibility study and was associated with high patient satisfaction and shorter measured administration time. CLINICAL

trial registrationClinicalTrials.gov identifier is NCT05340309.

Indexed as

digital patient monitoringhome administrationimmunotherapynon-small cell lung cancerSubcutaneous atezolizumab

Identifiers

PMID42830627
PMCPMC13644602

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.